# Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

> **NCT00479232** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 71 (actual)

## Conditions studied

- Leukemia, Myelocytic, Acute Myelodysplastic Syndromes
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** vorinostat
- **DRUG:** decitabine

## Key facts

- **NCT ID:** NCT00479232
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-06
- **Primary completion:** 2010-04
- **Final completion:** 2012-03
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2015-09-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00479232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00479232, "Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00479232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*